Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study.
Gundersen
S
S
Department of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Montebello, Oslo.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003606:Dacarbazine / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D014751:Vindesine / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D003606:Dacarbazine; D002945:Cisplatin; D014751:Vindesine